German drug maker STADA Arzneimittel AG said its Q3 earnings are burdened by problems in Serbia, where the customers of its subsidiary HemofarmVrsac cannot pay their debts, STADA said in a statement posted on its website. As a result of the liquidity problems of Serbian wholesalers, STADA said it expects one-off earnings burden worth about EUR 29.5mn before taxes in Q3. However, STADA'a management still considers the full-year target results achievable. |
|
Serbia's foreign debt rose an annual 4.7% y/y to EUR 25.4bn at end-February after climbing 6.6% on the year in January, central bank data showed. In monthly terms, however, the external ... more
Swedish company Ericsson said it has signed a five-year managed services contract with Vip Mobile - the Serbian arm of Telekom Austria Group. The agreement includes field maintenance services for ... more
Norwegian telecommunications firm Telenor and France's Societe General are seen as possible buyers of the Serbian unit of Belgium's KBC Group, which has been on sale for several years now, a ... more